These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
287 related items for PubMed ID: 9506732
1. Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males. Di Somma C, Colao A, Di Sarno A, Klain M, Landi ML, Facciolli G, Pivonello R, Panza N, Salvatore M, Lombardi G. J Clin Endocrinol Metab; 1998 Mar; 83(3):807-13. PubMed ID: 9506732 [Abstract] [Full Text] [Related]
4. Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism. Colao A, Di Somma C, Pivonello R, Loche S, Aimaretti G, Cerbone G, Faggiano A, Corneli G, Ghigo E, Lombardi G. J Clin Endocrinol Metab; 1999 Jun; 84(6):1919-24. PubMed ID: 10372687 [Abstract] [Full Text] [Related]
5. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B, Mockel J, Lamberigts G, Petrossians P, Coremans P, Mahler C, Stevenaert A, Verlooy J, Raftopoulos C, Beckers A. J Clin Endocrinol Metab; 1999 Jul; 84(7):2518-22. PubMed ID: 10404830 [Abstract] [Full Text] [Related]
6. Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing's disease. Di Somma C, Colao A, Pivonello R, Klain M, Faggiano A, Tripodi FS, Merola B, Salvatore M, Lombardi G. Clin Endocrinol (Oxf); 1998 May; 48(5):655-62. PubMed ID: 9666879 [Abstract] [Full Text] [Related]
7. Biomarkers of bone turnover and bone mineral density in hyperprolactinemic amenorrheic women. Shaarawy M, El-Dawakhly AS, Mosaad M, El-Sadek MM. Clin Chem Lab Med; 1999 Apr; 37(4):433-8. PubMed ID: 10369115 [Abstract] [Full Text] [Related]
8. Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine. De Rosa M, Colao A, Di Sarno A, Ferone D, Landi ML, Zarrilli S, Paesano L, Merola B, Lombardi G. Eur J Endocrinol; 1998 Mar; 138(3):286-93. PubMed ID: 9539303 [Abstract] [Full Text] [Related]
9. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. Rosen CJ, Chesnut CH, Mallinak NJ. J Clin Endocrinol Metab; 1997 Jun; 82(6):1904-10. PubMed ID: 9177404 [Abstract] [Full Text] [Related]
10. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ, MK-677/Alendronate Study Group. J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495 [Abstract] [Full Text] [Related]
15. Effects of short-term recombinant human insulin-like growth factor I administration on bone turnover in osteopenic women with anorexia nervosa. Grinspoon S, Baum H, Lee K, Anderson E, Herzog D, Klibanski A. J Clin Endocrinol Metab; 1996 Nov; 81(11):3864-70. PubMed ID: 8923830 [Abstract] [Full Text] [Related]
16. Biochemical markers of bone metabolism in mild ankylosing spondylitis and their relationship with bone mineral density and vertebral fractures. Mitra D, Elvins DM, Collins AJ. J Rheumatol; 1999 Oct; 26(10):2201-4. PubMed ID: 10529140 [Abstract] [Full Text] [Related]